Trial Profile
A biodegradable everolimus-eluting stent in acute coronary syndrome patients with unstable/ruptured plaques
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2013
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Acute coronary syndromes; Angina pectoris; Myocardial infarction
- Focus Therapeutic Use
- 07 Nov 2013 New trial record
- 04 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.